Skip to content

Propolis effects on depressive disorder

Evaluation of adjunctive therapy of propolis in the treatment of mild to moderate depression

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20170311033004N2
Enrollment
68
Registered
2018-08-29
Start date
2018-10-01
Completion date
Unknown
Last updated
2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression. Depressive episode In typical mild, moderate, or severe depressive episodes, the patient suffers from lowering of mood, reduction of energy, and decrease in activity. Capacity for enjoyment, interest, and concentration is reduced, and marked tiredness

Interventions

Intervention 1: Intervention group: Patients in this group will take a SSIRs anti-dep ression medicine with Propolis (2000mg/70kg) during 6 weeks. Intervention 2: Control group: This group receives th

Sponsors

Academic Center for Education, Culture and Research (ACECR)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Individuals with diagnosis of mild-moderate depression according HDRS score Age between 18-25 Outpatient Patients with no comorbid disorders diabetes, high blood pressure or cardiovascular disease Patients with no comorbid mental condition No consumption drugs other than SSRI Non-pregnant

Exclusion criteria

Exclusion criteria: Diagnosis of another non-depression disorder for patient during study Suicide inclination Taking anti depression medication except SSRI or electroconvulsive therapy impossibility to track disease (absence at the time of visit, cancellation of the continuation of the study and death) Occurrence of allergic reaction Occurrence of some side effect disorders such as fever, digestive and heart complications due to drug intake Hospitalization

Design outcomes

Primary

MeasureTime frame
Formulation and primary sample. Timepoint: 6 months. Method of measurement: quantitative.

Secondary

MeasureTime frame
Clinical trials. Timepoint: 22th month. Method of measurement: questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Razmi

Academic Center for Education, Culture and Research (ACECR)

arazmi@alumnus.tums.ac.ir+98 26 3476 4015

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026